Shanghai Junshi Biosciences Co.Ltd(688180) : the PFS of nasopharyngeal carcinoma patients treated with treprizumab combined with chemotherapy reached 21.4 months

The 113th annual meeting of the American Association for cancer research (AACR) in 2022 was held from April 8 to 13. At this conference, the latest research results of Shanghai Junshi Biosciences Co.Ltd(688180) products were announced. Among them, the phase III clinical trial of treprizumab combined with chemotherapy versus placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (rmnpc) (jupiter-02 study), led by Professor Xu Ruihua of the cancer prevention and treatment center of Sun Yat sen University, updated the analysis results of the final progression free survival (PFS) and medium-term overall survival (OS), and displayed them in the form of wall newspaper. The results showed that compared with the placebo combined chemotherapy group, the median PFS in the treprizumab combined chemotherapy group was significantly prolonged, which was 21.4 vs 8.2 months, extended by 13.2 months, treprizumab combined with chemotherapy can reduce the risk of disease progression or death by 48%.